Sarepta Therapeutics (SRPT) Tops Q1 EPS by 75c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of $0.73, $0.75 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $413.5 million versus the consensus estimate of $379.15 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Wolfe Research Upgrades Sarepta Therapeutics (SRPT) to Outperform
• Enovix, Forte Biosciences rally premarket; PepsiCo slips
• Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance